Firmagon (degarelix) is a protein pharmaceutical. Degarelix was first approved as Firmagon on 2008-12-24. It is used to treat prostatic neoplasms in the USA. It has been approved in Europe to treat prostatic neoplasms. The pharmaceutical is active against gonadotropin-releasing hormone receptor. Firmagon's patents are valid until 2032-04-27 (FDA).
|Drug Class||Hormone-release inhibiting peptides|